top of page

Tackling the Serious Global Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases

Appili Therapeutics Infectiou Disease Drug Development Program

Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.

Leadership team skilled in advancing programs with upside potential

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives

LATEST NEWS RELEASES

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
1/17/2023
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
1/13/2023
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
11/15/2022
Company Conference Room

LATEST EVENTS

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
1/17/2023
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
1/13/2023
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
11/15/2022
bottom of page